MCID: PNC053
MIFTS: 39

Pancreatic Islet Cell Tumors

Categories: Rare diseases, Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Islet Cell Tumors

MalaCards integrated aliases for Pancreatic Islet Cell Tumors:

Name: Pancreatic Islet Cell Tumors 49 69
Pancreatic Endocrine Carcinoma 69
Islet of Langerhans Tumor 49
Islet Cell Carcinoma 49
Islet Cell Tumors 49
Islet Cell Tumor 69

Classifications:



External Ids:

UMLS 69 C2931039

Summaries for Pancreatic Islet Cell Tumors

NIH Rare Diseases : 49 This condition doesn't have a summary yet. Please see our page(s) on Neuroendocrine tumor.

MalaCards based summary : Pancreatic Islet Cell Tumors, also known as pancreatic endocrine carcinoma, is related to multiple endocrine neoplasia and islet cell tumor. An important gene associated with Pancreatic Islet Cell Tumors is SST (Somatostatin), and among its related pathways/superpathways is Signaling by GPCR. The drugs Pancreatic Polypeptide and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include pancreatic islet, liver and pancreas.

Related Diseases for Pancreatic Islet Cell Tumors

Diseases related to Pancreatic Islet Cell Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 99)
# Related Disease Score Top Affiliating Genes
1 multiple endocrine neoplasia 30.3 CALCA MEN1
2 islet cell tumor 30.1 CALCA GAST INS MEN1 SST
3 duodenitis 30.1 GAST INS
4 pheochromocytoma 29.9 CALCA MEN1 SST
5 acromegaly 29.9 INS MEN1 SST
6 insulinoma 29.9 INS MEN1 SST
7 somatostatinoma 29.8 CALCA INS SST
8 multiple endocrine neoplasia, type i 29.6 GAST INS MEN1 SST
9 von hippel-lindau syndrome 29.5 MEN1 TSC2
10 hyperparathyroidism 29.4 CALCA GAST MEN1
11 gastrinoma 29.1 GAST INS MEN1 SST
12 pancreatic endocrine carcinoma 11.1
13 pancreatitis 10.8
14 postural hypotension 10.3 INS SST
15 hyperpituitarism 10.3 INS SST
16 wdha syndrome 10.3 CALCA SST
17 prolactin producing pituitary tumor 10.3 CALCA SST
18 endocrine pancreas disease 10.3 INS SST
19 pituitary-dependent cushing's disease 10.3 INS SST
20 gastrointestinal neuroendocrine benign tumor 10.3 GAST SST
21 gastric neuroendocrine neoplasm 10.3 GAST SST
22 pylorospasm 10.3 GAST SST
23 hormone producing pituitary cancer 10.3 MEN1 SST
24 pancreas disease 10.3 INS SST
25 postcholecystectomy syndrome 10.2 GAST SST
26 autonomic nervous system disease 10.2 CALCA INS
27 retinitis pigmentosa 40 10.2 GAST SST
28 carcinoid tumors, intestinal 10.2 MEN1 SST
29 pernicious anemia 10.2 GAST SST
30 functioning pituitary adenoma 10.2 MEN1 SST
31 fibrous dysplasia 10.2 CALCA SST
32 duodenum cancer 10.2 MEN1 SST
33 gastric neuroendocrine tumor 10.2 CALCA GAST
34 ectopic cushing syndrome 10.2 MEN1 SST
35 mixed ductal-endocrine carcinoma 10.2 GAST SST
36 endocrine organ benign neoplasm 10.2 MEN1 SST
37 pituitary tumors 10.2 MEN1 SST
38 thyroid gland disease 10.2 CALCA INS
39 multiple endocrine neoplasia, type iib 10.2 CALCA MEN1
40 gallbladder disease 10.2 INS SST
41 ovarian cystic teratoma 10.2 CALCA GAST
42 stomach disease 10.1 GAST SST
43 parathyroid gland disease 10.1 CALCA MEN1
44 duodenal gastrinoma 10.1 GAST MEN1
45 parathyroid carcinoma 10.1 CALCA MEN1
46 organ system benign neoplasm 10.1 MEN1 SST
47 multiple endocrine neoplasia, type iia 10.1 CALCA MEN1
48 paraganglioma 10.1 CALCA SST
49 constipation 10.1 GAST SST
50 pituitary adenoma, prolactin-secreting 10.1 MEN1 SST

Graphical network of the top 20 diseases related to Pancreatic Islet Cell Tumors:



Diseases related to Pancreatic Islet Cell Tumors

Symptoms & Phenotypes for Pancreatic Islet Cell Tumors

Drugs & Therapeutics for Pancreatic Islet Cell Tumors

Drugs for Pancreatic Islet Cell Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
2 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
3
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
4
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
5
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
6
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
7
Sunitinib Approved, Investigational Phase 3,Phase 2 341031-54-7, 557795-19-4 5329102
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 143 6006
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
11 Angiogenesis Inhibitors Phase 2, Phase 3, Phase 1
12 Angiogenesis Modulating Agents Phase 2, Phase 3, Phase 1
13 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
14 Antimetabolites Phase 2, Phase 3,Phase 1
15 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
16 Analgesics Phase 3
17 Central Nervous System Depressants Phase 3
18 Adjuvants, Anesthesia Phase 3
19 Narcotics Phase 3
20 Analgesics, Opioid Phase 3
21 Anesthetics Phase 3
22 Anesthetics, General Phase 3
23 Anesthetics, Intravenous Phase 3
24 Peripheral Nervous System Agents Phase 3
25 Folate Nutraceutical Phase 2, Phase 3
26 Vitamin B9 Nutraceutical Phase 2, Phase 3
27 Cola Nutraceutical Phase 3,Phase 2,Phase 1
28
Somatostatin Approved, Investigational Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
29
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
30
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
31
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
32
Melphalan Approved Phase 2 148-82-3 460612 4053
33
Pantoprazole Approved Phase 2 102625-70-7 4679
34
Omeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6 4594
35
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
36
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
37
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 6400441 383414
38
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
39
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
40
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
41
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
42
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
43
Pancrelipase Approved, Investigational Phase 2 53608-75-6
44
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
45
Dacarbazine Approved, Investigational Phase 1, Phase 2 4342-03-4 5351166
46
Temozolomide Approved, Investigational Phase 1, Phase 2 85622-93-1 5394
47
Lenograstim Approved, Investigational Phase 2 135968-09-1
48
Menthol Approved Phase 1, Phase 2 2216-51-5 16666
49
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
50
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938

Interventional clinical trials:

(show top 50) (show all 57)

# Name Status NCT ID Phase Drugs
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors Terminated NCT00428597 Phase 3 sunitinib malate;Placebo
5 A Study of IMC-A12 in Islet Cell Cancer Completed NCT00781911 Phase 2 depot octreotide
6 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
7 RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma Completed NCT00113360 Phase 2 RAD001;Octreotide Depot
8 Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Completed NCT00434109 Phase 2 Sunitinib malate
9 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
10 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
11 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
12 Pazopanib as Single Agent in Advanced NETs Completed NCT01280201 Phase 2 Pazopanib
13 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
14 Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) Completed NCT01169649 Phase 2 MK-2206
15 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
16 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
17 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
18 Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases Completed NCT00019786 Phase 2 isolated perfusion;melphalan
19 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2 temsirolimus
20 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
21 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
22 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer Completed NCT01396382 Phase 2
23 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
24 FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas Recruiting NCT03042780 Phase 2 FOLFIRINOX;Granulocyte colony-stimulating factor (G-CSF)
25 Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Recruiting NCT01465659 Phase 1, Phase 2 temozolomide;pazopanib hydrochloride
26 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
27 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
28 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
29 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Not yet recruiting NCT02038738 Phase 1, Phase 2 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
30 Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET Terminated NCT01374451 Phase 2 Everolimus;Pasireotide LAR
31 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
32 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
33 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
34 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
35 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
36 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
37 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
38 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
39 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
40 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
41 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
42 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
43 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
44 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
45 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
46 Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors Unknown status NCT00569738
47 Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome Completed NCT00001254
48 Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. Completed NCT01398306
49 Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract Completed NCT01770405
50 A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. Completed NCT00428220 sunitinib

Search NIH Clinical Center for Pancreatic Islet Cell Tumors

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Pancreatic Islet Cell Tumors

Anatomical Context for Pancreatic Islet Cell Tumors

MalaCards organs/tissues related to Pancreatic Islet Cell Tumors:

38
Pancreatic Islet, Liver, Pancreas, Lymph Node, Kidney, Breast, Bone

Publications for Pancreatic Islet Cell Tumors

Articles related to Pancreatic Islet Cell Tumors:

(show top 50) (show all 97)
# Title Authors Year
1
Characterization of pancreatic islet cell tumors and renal tumors induced by a combined treatment of streptozotocin and nicotinamide in male SD rats. ( 28390812 )
2017
2
Characterization of a pancreatic islet cell tumor in a polar bear (Ursus maritimus). ( 25273481 )
2014
3
Metastatic Insulinoma Following Resection of Nonsecreting Pancreatic Islet Cell Tumor: A Case Report and Review of the Literature. ( 26425568 )
2013
4
Surgical treatment of pancreatic islet cell tumor: report of 44 cases. ( 24719954 )
2013
5
Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors. ( 23346016 )
2012
6
Pancreatic and peri-pancreatic lesions mimic pancreatic islet cell tumor in multidetector computed tomography. ( 21740785 )
2011
7
Diffusion weighted MR imaging of pancreatic islet cell tumors. ( 19264435 )
2010
8
Systematic comparison of sporadic and syndromic pancreatic islet cell tumors. ( 20660572 )
2010
9
Pancreatic islet cell tumor secreting insulin-like growth factor type-II in a dog. ( 19780935 )
2009
10
Spontaneous pancreatic islet cell tumor in a black and white colobus monkey (Colobus guereza kikuyuensis). ( 18269522 )
2008
11
Hypoglycemia associated with the production of insulin-like growth factor II in a pancreatic islet cell tumor: a case report. ( 18490836 )
2008
12
Extensive acrochordons and pancreatic islet-cell tumors in tuberous sclerosis associated with TSC2 mutations. ( 16835931 )
2006
13
Multi-detector row CT of pancreatic islet cell tumors. ( 16549609 )
2006
14
Surgical treatment of non-functioning pancreatic islet cell tumors. ( 15719379 )
2005
15
Non-islet origin of pancreatic islet cell tumors. ( 15070966 )
2004
16
Endoscopic ultrasonography of nonfunctioning pancreatic islet cell tumors with histologic correlation. ( 15532784 )
2004
17
Pancreatic islet cell tumor in a domestic ferret. ( 14615962 )
2003
18
High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis. ( 11929809 )
2002
19
Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 cases (1989-1999). ( 12322919 )
2002
20
Induction of pancreatic islet cell tumors in rats by repeated intravenous administration of 4-hydroxyaminoquinoline 1-oxide. ( 11442018 )
2001
21
Sonographic diagnosis of pancreatic islet cell tumor: value of intermittent harmonic imaging. ( 11579405 )
2001
22
Ultrasound-guided laparoscopic resection of pancreatic islet cell tumors. ( 10872980 )
2000
23
Evaluation of pancreatic islet cell tumors by fluorine-18 fluorodeoxyglucose positron emission tomography: comparison with other modalities. ( 10656646 )
2000
24
Large and asymptomatic pancreatic islet cell tumor in a patient with multiple endocrine neoplasia type 1. ( 11216636 )
2000
25
Pancreatitis associated with pancreatic islet cell tumors. ( 10414710 )
1999
26
Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. ( 9854581 )
1998
27
Functional pancreatic islet cell tumors with liver metastasis: the role of cytoreductive surgery and transcatheter arterial chemoembolization: a report of five cases. ( 9884450 )
1998
28
Surgical decision-making affected by clinical and genetic screening of a novel kindred with von Hippel-Lindau disease and pancreatic islet cell tumors. ( 9488521 )
1998
29
Chromogranin A plasma concentration and expression in pancreatic islet cell tumors of dogs and cats. ( 9185968 )
1997
30
Pancreatic polypeptide is a useful plasma marker for radiographically evident pancreatic islet cell tumors in patients with multiple endocrine neoplasia type 1. ( 9426414 )
1997
31
Pancreatic islet cell tumor producing vasoactive intestinal polypeptide and calcitonin. ( 9494586 )
1997
32
A growth hormone-releasing hormone-producing pancreatic islet cell tumor metastasized to the pituitary is associated with pituitary somatotroph hyperplasia and acromegaly. ( 9253362 )
1997
33
Absence of RET proto-oncogene mutations in a father and son with pheochromocytoma and pancreatic islet cell tumor. ( 9179691 )
1997
34
Immunohistochemistry of pancreatic islet cell tumors in the ferret (Mustela putorius furo). ( 9381649 )
1997
35
[Immunohistochemical studies of nonsecreting pancreatic islet cell tumors secreting many hormones]. ( 9388878 )
1996
36
Diagnosis and treatment of insulin-secreting pancreatic islet cell tumors in ferrets: 57 cases (1986-1994). ( 8921033 )
1996
37
Comparison of chromogranin A and pancreastatin levels in plasma of patients with pancreatic islet cell tumor. ( 7630318 )
1995
38
The concurrence of duodenal epithelioid stromal sarcoma, pulmonary chondromatous hamartoma, and nonfunctioning pancreatic islet cell tumor. A possible analogue of Carney's triad? ( 8060238 )
1994
39
Comparison of plasma pancreastatin and GAWK concentrations, presumed processing products of chromogranin A and B, in plasma of patients with pancreatic islet cell tumors. ( 8288164 )
1993
40
Surgical experience with pancreatic islet-cell tumors. ( 8105769 )
1993
41
Islet amyloid polypeptide-producing pancreatic islet cell tumor. A clinical and biochemical characterization. ( 1326785 )
1992
42
Subcutaneous fat necrosis associated with pancreatic islet cell tumor. ( 1314524 )
1992
43
7B2, a possible marker for nonfunctioning pancreatic islet cell tumor. ( 1662184 )
1991
44
Endoscopic ultrasonography in the diagnosis of pancreatic islet cell tumors. ( 1646897 )
1991
45
Non-functioning pancreatic islet cell tumor presenting with gastrointestinal hemorrhage. ( 1655645 )
1991
46
Pancreastatin producing cell line from human pancreatic islet cell tumor. ( 2159299 )
1990
47
Hyperinsulinism and hypoglycemia associated with pancreatic islet cell tumor in a ferret. ( 2537277 )
1989
48
Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. ( 2537716 )
1989
49
Pancreatic islet cell tumors metastatic to the liver: treatment by hepatic artery chemo-embolization. ( 2559021 )
1989
50
The role of morphometry in predicting prognosis in pancreatic islet cell tumors. ( 2544252 )
1989

Variations for Pancreatic Islet Cell Tumors

Expression for Pancreatic Islet Cell Tumors

Search GEO for disease gene expression data for Pancreatic Islet Cell Tumors.

Pathways for Pancreatic Islet Cell Tumors

Pathways related to Pancreatic Islet Cell Tumors according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.86 CALCA GAST INS MEN1 NTS SST

GO Terms for Pancreatic Islet Cell Tumors

Cellular components related to Pancreatic Islet Cell Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.02 CALCA GAST INS NTS SST

Biological processes related to Pancreatic Islet Cell Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.58 MEN1 SST TSC2
2 cell-cell signaling GO:0007267 9.5 CALCA INS SST
3 cellular protein metabolic process GO:0044267 9.43 CALCA INS MEN1
4 response to heat GO:0009408 9.37 CALCA SST
5 G-protein coupled receptor signaling pathway GO:0007186 9.35 CALCA GAST INS NTS SST
6 positive regulation of blood vessel diameter GO:0097755 9.16 CALCA INS
7 regulation of receptor activity GO:0010469 9.02 CALCA GAST INS NTS SST

Molecular functions related to Pancreatic Islet Cell Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.92 CALCA GAST INS SST

Sources for Pancreatic Islet Cell Tumors

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....